Sigma Healthcare (ASX:SIG) raised its fiscal 2025 normalized earnings before interest and tax guidance to a range of AU$64 to AU$70 million, up from the previous guidance of AU$50 to AU$60 million, according to a Friday filing with the Australian bourse.

The increase follows strong performance, particularly from the Chemist Warehouse supply contract that started on July 1, 2024, the filing said.

Statutory net profit after tax for the fiscal year will be "significantly" impacted by non-recurring merger costs, including changes to performance rights, subject to audit completion, the filing added.

The company's shares rose past 5% in recent Friday trade.